Yet another approach is to block BCR signaling further downstream with a MALT1 protease inhibitor, MI-2, as previously explored in ABC cell line and mouse models, but whether induced mutations within the MALT1 protease active site itself will lead to resistance in patients remains unknown [17]. This evidence concerns the gene BCR and aneurysmal bone cyst.